HIV News and Research

RSS

Clinical trial shows no benefit of tamoxifen in treating deadly fungal meningitis

Hopes that tamoxifen could improve survival for a deadly form of fungal meningitis have been dashed by clinical trial results published in eLife.

26 Oct 2021

Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

Israeli researchers evaluate the antibody response in ICPs to assess antibody-mediated immunity following vaccination with the Pfizer-BioNTech vaccine.

26 Oct 2021

NIH invests $74.5 million to advance data science research and spur health discoveries across Africa

The National Institutes of Health is investing about $74.5 million over five years to advance data science, catalyze innovation and spur health discoveries across Africa.

26 Oct 2021

Case Western Reserve secures $16 million to understand the relation between substance use and HIV

The use of opioids, methamphetamines, cocaine and other stimulants is the second-most-common cause of exposure to HIV among those in the United States diagnosed with the virus that causes AIDS.

25 Oct 2021

Role of SARS-CoV-2 infection biomarkers in HIV replication

A new study investigates the role of the S100A8/A9 complex in the replication of HIV.

25 Oct 2021

Hydrogel-based vaccine delivery system evokes antibody response against SARS-CoV-2

Researchers from Stanford University have been attempting to create a hydrogel-based vaccine delivery system that could improve the immune response's strength and duration.

22 Oct 2021

STI and HIV services in crisis pregnancy centers could cause real harm to public health

Cases of sexually transmitted infections (STIs) and HIV are again on the rise in the U.S., giving new urgency to ongoing efforts to make STI and HIV services more accessible.

21 Oct 2021

Expert sound alarm on the crisis in sex education across the U.S.

Experts at the Society for Adolescent Health and Medicine (SAHM) are calling attention to a crisis in sex education, specifically the continued creation and endorsement of abstinence-only curricula being taught across the U.S.

21 Oct 2021

Investigational inhaled COVID-19 treatment graduates to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that the external data and safety monitoring board (DSMB) has recommended that SNG001, an inhaled formulation of interferon beta, advance to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

21 Oct 2021

Novel trial uses a virtual village to treat HIV-associated loneliness

A new clinical trial designed by Maile Young Karris, MD, internal medicine physician and infectious disease specialist at UC San Diego Health, seeks to discover whether people living with HIV can benefit from emotional support offered by a virtual community, and from physical support and services delivered by community volunteers.

21 Oct 2021

Duke awarded NIAID funding to develop the next generation of pan-coronavirus vaccines

The National Institute of Allergy and Infectious Diseases has awarded $17.5 million over three years to the Duke Human Vaccine Institute to develop a vaccine that protects against multiple types of coronaviruses and viral variants.

21 Oct 2021

Novel Einstein-developed strategy successfully suppresses HIV infections in mice

Armed with a novel strategy they developed for bolstering the body's immune response, scientists at Albert Einstein College of Medicine have successfully suppressed HIV infections in mice-;offering a path to a functional cure for HIV and other chronic viral infections.

21 Oct 2021

Antidepressant Prozac could offer the first treatment for atrophic macular degeneration

An antidepressant best known as Prozac could offer the first treatment for the leading cause of blindness among people over 50, new research from the University of Virginia School of Medicine suggests.

21 Oct 2021

Suggested mechanism of SARS-CoV-2 infection inhibition by Mitoxantrone

A group of researchers performed a drug repurposing screen on an FDA-approved anti-cancer drug named Mitoxantrone.

20 Oct 2021

COVID-19 vaccine breakthrough infections among immunocompromised individuals

A study of breakthrough infections in immunocompromised people following two doses of the Pfizer/BioNTech vaccine against SARS-CoV-2 concluded that immunocompromised people would be best served with a third dose of the vaccine for better protection.

19 Oct 2021

Nasal delivery of single-domain antibodies improves SARS-CoV-2 symptoms in animal model

In a recent study published in the journal PLOS Pathogens, scientists showed that nasal administration of a single-domain antibody (VHH), named K-874A, brought about inhibition of SARS-CoV-2 titers in infected lungs of Syrian hamsters.

19 Oct 2021

UChicago and Rush secure NIH grant to launch the Chicago Chronic Condition Equity Network

The University of Chicago and Rush University have received a $20M, five-year grant from the National Institutes of Health to establish a Center for Multiple Chronic Diseases Associated with Health Disparities.

18 Oct 2021

Coronavirus vaccines and prior infections can provide broad immunity against similar viruses

Northwestern Medicine scientists have shown for the first time that coronavirus vaccines and prior coronavirus infections can provide broad immunity against other, similar coronaviruses. The findings build a rationale for universal coronavirus vaccines that could prove useful in the face of future epidemics.

18 Oct 2021

New method to study the nuclear pore complex directly inside cells

Context matters. It's true for many facets of life, including the tiny molecular machines that perform vital functions inside our cells.

18 Oct 2021

New class of CXCR4 antagonists could prevent airway inflammation and atopic dermatitis

Aberrant CXCR4/CXCL12 signaling is involved in many pathophysiological processes such as cancer and inflammatory diseases. A natural fragment of serum albumin, named EPI-X4, has previously been identified as endogenous peptide antagonist andinverse agonistof CXCR4 and is a promising compound for the development of improved analogues for the therapy of CXCR4-associated diseases.

18 Oct 2021

HIV News and Research

Clinical trial shows no benefit of tamoxifen in treating deadly fungal meningitis

Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

NIH invests $74.5 million to advance data science research and spur health discoveries across Africa

Case Western Reserve secures $16 million to understand the relation between substance use and HIV

Role of SARS-CoV-2 infection biomarkers in HIV replication

Hydrogel-based vaccine delivery system evokes antibody response against SARS-CoV-2

STI and HIV services in crisis pregnancy centers could cause real harm to public health

Expert sound alarm on the crisis in sex education across the U.S.

Investigational inhaled COVID-19 treatment graduates to phase 3 in ACTIV-2 trial

Novel trial uses a virtual village to treat HIV-associated loneliness

Duke awarded NIAID funding to develop the next generation of pan-coronavirus vaccines

Novel Einstein-developed strategy successfully suppresses HIV infections in mice

Antidepressant Prozac could offer the first treatment for atrophic macular degeneration

Suggested mechanism of SARS-CoV-2 infection inhibition by Mitoxantrone

COVID-19 vaccine breakthrough infections among immunocompromised individuals

Nasal delivery of single-domain antibodies improves SARS-CoV-2 symptoms in animal model

UChicago and Rush secure NIH grant to launch the Chicago Chronic Condition Equity Network

Coronavirus vaccines and prior infections can provide broad immunity against similar viruses

New method to study the nuclear pore complex directly inside cells

New class of CXCR4 antagonists could prevent airway inflammation and atopic dermatitis

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News